Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) - QUENCH

Study identifier:D1443L00062

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) with daily dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients

Medical condition

schizophrenia

Phase

Phase 4

Healthy volunteers

No

Study drug

Quetiapine Fumarate XR

Sex

All

Actual enrollment

96

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2008
Primary Completion Date: 01 Jul 2009
Study Completion Date: 01 Jul 2009

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 May 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria